Markus F. Scheerer

1.8k citations

38 papers · 753 indexed · 1 hit paper · h-index 19

Impact in

Endocrinology, Diabetes and Metabolism top 2%
- Diabetes Treatment and Management
- Diabetes Management and Research
- Hormonal Regulation and Hypertension
Nephrology top 10%

Papers in ⓘ

Endocrinology, Diabetes and Metabolism 29
- Diabetes Treatment and Management 22
- Diabetes Management and Research 13
- Hormonal Regulation and Hypertension 11
Cardiology and Cardiovascular Medicine 10
- Heart Failure Treatment and Management 7
- Cardiovascular Function and Risk Factors 4
- Blood Pressure and Hypertension Studies 2

Co-authors: Moshe Phillip (7 shared papers)Peter Rossing (7 shared papers)Chantal Mathieu (7 shared papers)Fredrik Thorén (8 shared papers)Paresh Dandona (6 shared papers)Nayyar Iqbal (4 shared papers)Stefan D. Anker (5 shared papers)John Xu (6 shared papers)
Journals: Diabetes (5 papers)Diabetes Obesity and Metabolism (5 papers)Journal of the American College of Cardiology (3 papers)JACC Heart Failure (2 papers)Journal of the American Society of Nephrology (2 papers)
Partner nations: Germany United States United Kingdom

In The Last Decade

Markus F. Scheerer

34 papers receiving 741 citations

Hit Papers

align trajectories log scale

Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes 2025 · 44 citations

Peers

Countries citing papers authored by Markus F. Scheerer

Since Specialization

Citations

This map shows the geographic impact of Markus F. Scheerer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Markus F. Scheerer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Markus F. Scheerer more than expected).

Fields of papers citing papers by Markus F. Scheerer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Markus F. Scheerer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Markus F. Scheerer. The network helps show where Markus F. Scheerer may publish in the future.

Co-authors

The 25 scholars most cited alongside Markus F. Scheerer, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Markus F. Scheerer Line = papers co-authored together Markus F. Scheerer links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 38 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Finerenone in Predominantly Advanced CKD and Type 2 Diabetes With or Without Sodium-Glucose Cotransporter-2 Inhibitor Therapy Kidney International Reports ·Peter Rossing, Gerasimos Filippatos, Rajiv Agarwal, Stefan D. Anker, Bertram Pitt, Luís M. Ruilope, Juliana C.N. Chan, Adriaan Kooy, Kieran McCafferty, Guntram Schernthaner, Christoph Wanner, Amer Joseph, Markus F. Scheerer, Charlie Scott, George L. Bakris	2021	101
2	Effect of dapagliflozin as an adjunct to insulin over 52 weeks in individuals with type 1 diabetes: post-hoc renal analysis of the DEPICT randomised controlled trials The Lancet Diabetes & Endocrinology ·Per‐Henrik Groop, Paresh Dandona, Moshe Phillip, Pieter Gillard, Steven V. Edelman, Johan Jendle, John Xu, Markus F. Scheerer, Fredrik Thorén, Nayyar Iqbal, Enrico Repetto, Chantal Mathieu	2020	53
3	Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes New England Journal of Medicine ·Rajiv Agarwal, Jennifer B. Green, Hiddo J.L. Heerspink, Johannes F.E. Mann, Janet B. McGill, Amy K. Mottl, Julio Rosenstock, Peter Rossing, Muthiah Vaduganathan, Meike Brinker, Robert Edfors, Na Li, Markus F. Scheerer, Charlie Scott, Masaomi Nangaku Hit paper breakdown →	2025	44
4	Long‐term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT ‐2 study): 52‐week results from a randomized controlled trial Diabetes Obesity and Metabolism ·Chantal Mathieu, Gottfried Rudofsky, Moshe Phillip, Eiichi Araki, Marcus Lind, Niki Arya, Fredrik Thorén, Markus F. Scheerer, Nayyar Iqbal, Paresh Dandona	2020	43
5	Add‐on therapy with dapagliflozin under full closed loop control improves time in range in adolescents and young adults with type 1 diabetes: The DAPADream study Diabetes Obesity and Metabolism ·Torben Biester, Ido Muller, Thekla von dem Berge, Eran Atlas, Revital Nimri, Moshe Phillip, Tadej Battelino, Nataša Bratina, Klemen Dovč, Markus F. Scheerer, Olga Kordonouri, Thomas Danne	2020	40
6	Kidney outcomes with finerenone: an analysis from the FIGARO-DKD study Nephrology Dialysis Transplantation ·Luís M. Ruilope, Bertram Pitt, Stefan D. Anker, Peter Rossing, Csaba P. Kövesdy, Roberto Pecoits‐Filho, Pablo E. Pérgola, Amer Joseph, Andrea Lage, Nicole Mentenich, Markus F. Scheerer, George L. Bakris	2022	39
7	Machine Learning Approaches Reveal Metabolic Signatures of Incident Chronic Kidney Disease in Individuals With Prediabetes and Type 2 Diabetes Diabetes ·Jialing Huang, Cornelia Huth, Marcela Covic, Martina Troll, Jonathan Adam, Sven Zukunft, Cornelia Prehn, Li Wang, Jana Nano, Markus F. Scheerer, Susanne Neschen, Gabi Kastenmüller, Karsten Suhre, Michael Laxy, Freimut Schliess, Christian Gieger, Jerzy Adamski, Martin Hrabě de Angelis, Annette Peters, Rui Wang‐Sattler	2020	39
8	Effects of canagliflozin versus finerenone on cardiorenal outcomes: exploratory post hoc analyses from FIDELIO-DKD compared to reported CREDENCE results Nephrology Dialysis Transplantation ·Rajiv Agarwal, Stefan D. Anker, Gerasimos Filippatos, Bertram Pitt, Peter Rossing, Luís M. Ruilope, John Boletis, Robert Toto, Guillermo E. Umpierrez, Christoph Wanner, Takashi Wada, Charlie Scott, Amer Joseph, Ike Ogbaa, Luke Roberts, Markus F. Scheerer, George L. Bakris	2021	36
9	Dapagliflozin effects on haematocrit, red blood cell count and reticulocytes in insulin-treated patients with type 2 diabetes Scientific Reports ·Jens Aberle, Markus Menzen, Sebastian Schmid, Christoph Terkamp, Elmar Jaeckel, Katja Rohwedder, Markus F. Scheerer, John Xu, Weifeng Tang, Andreas L. Birkenfeld	2020	33
10	Retinal proteome alterations in a mouse model of type 2 diabetes Diabetologia ·Alice Ly, Markus F. Scheerer, Sven Zukunft, Caroline Muschet, Juliane Merl, Jerzy Adamski, Martin Hrabě de Angelis, Susanne Neschen, Stefanie M. Hauck, Marius Ueffing	2013	32
11	Effects of dapagliflozin on insulin‐requirement, glucose excretion and ß‐hydroxybutyrate levels are not related to baseline HbA1c in youth with type 1 diabetes Diabetes Obesity and Metabolism ·Torben Biester, Baerbel Aschemeier, Maryam Fath, M Frey, Markus F. Scheerer, Olga Kordonouri, Thomas Danne	2017	30
12	Metformin Supports the Antidiabetic Effect of a Sodium Glucose Cotransporter 2 Inhibitor by Suppressing Endogenous Glucose Production in Diabetic Mice Diabetes ·Susanne Neschen, Markus F. Scheerer, Anett Seelig, Peter Huypens, Jürgen Schultheiß, Moya Wu, Wolfgang Wurst, Birgit Rathkolb, Karsten Suhre, Eckhard Wolf, Johannes Beckers, Martin Hrabě de Angelis	2014	29
13	Rationale and design of a randomised phase III registration trial investigating finerenone in participants with type 1 diabetes and chronic kidney disease: The FINE-ONE trial Diabetes Research and Clinical Practice ·Hiddo J.L. Heerspink, Andreas L. Birkenfeld, David Z.I. Cherney, Helen M. Colhoun, Linong Ji, Chantal Mathieu, Per‐Henrik Groop, Richard E. Pratley, Sylvia E. Rosas, Peter Rossing, Jay S. Skyler, Katherine R. Tuttle, Robert Lawatscheck, Charlie Scott, Robert Edfors, Markus F. Scheerer, Peter Kolkhof, Janet B. McGill	2023	27
14	Long‐term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: pooled 52‐week outcomes from the DEPICT ‐1 and ‐2 studies Diabetes Obesity and Metabolism ·Moshe Phillip, Chantal Mathieu, Marcus Lind, Eiichi Araki, Paolo Di Bartolo, Richard M. Bergenstal, Simon Heller, Lars Hansen, Markus F. Scheerer, Fredrik Thorén, Niki Arya, John Xu, Nayyar Iqbal, Paresh Dandona, (unknown)	2020	26
15	Effects of the Nonsteroidal MRA Finerenone With and Without Concomitant SGLT2 Inhibitor Use in Heart Failure Circulation ·Muthiah Vaduganathan, Brian Claggett, Ian J. Kulac, Zi Michael Miao, Akshay S. Desai, Pardeep S. Jhund, Alasdair Henderson, Meike Brinker, James Lay‐Flurrie, Prabhakar Viswanathan, Markus F. Scheerer, Andrea Lage, Carolyn S.P. Lam, Michele Senni, Sanjiv J. Shah, Adriaan A. Voors, Faı̈ez Zannad, Bertram Pitt, John J.V. McMurray, Scott D. Solomon	2024	25
16	Benefit/risk profile of dapagliflozin 5 mg in the DEPICT ‐1 and ‐2 trials in individuals with type 1 diabetes and body mass index ≥27 kg/m ² Diabetes Obesity and Metabolism ·Chantal Mathieu, Paresh Dandona, Andreas L. Birkenfeld, Troels Krarup Hansen, Nayyar Iqbal, John Xu, Enrico Repetto, Markus F. Scheerer, Fredrik Thorén, Moshe Phillip	2020	24
17	Importance of Sulfur-Containing Metabolites in Discriminating Fecal Extracts between Normal and Type-2 Diabetic Mice Journal of Proteome Research ·Alesia Walker, Marianna Lucio, Barbara Pfitzner, Markus F. Scheerer, Susanne Neschen, Martin Hrabě de Angelis, Anton Hartmann, Philippe Schmitt‐Kopplin	2014	24
18	Changes in HbA1c, body weight, and systolic blood pressure in type 2 diabetes patients initiating dapagliflozin therapy: a primary care database study Diabetes Metabolic Syndrome and Obesity ·Markus F. Scheerer, R Rist, O Proske, Annika Meng, Karel Kostev	2016	22
19	Finerenone and Kidney Outcomes in Patients With Heart Failure Journal of the American College of Cardiology ·Finnian R. Mc Causland, Muthiah Vaduganathan, Brian Claggett, Ian J. Kulac, Akshay S. Desai, Pardeep S. Jhund, Alasdair Henderson, Meike Brinker, Robert Perkins, Markus F. Scheerer, Patrick Schloemer, Carolyn S.P. Lam, Michele Senni, Sanjiv J. Shah, Adriaan A. Voors, Faı̈ez Zannad, Bertram Pitt, John J.V. McMurray, Scott D. Solomon	2024	21
20	Validation of Candidate Phospholipid Biomarkers of Chronic Kidney Disease in Hyperglycemic Individuals and Their Organ-Specific Exploration in Leptin Receptor-Deficient db/db Mouse Metabolites ·Jialing Huang, Marcela Covic, Cornelia Huth, Martina Rommel, Jonathan Adam, Sven Zukunft, Cornelia Prehn, Li Wang, Jana Nano, Markus F. Scheerer, Susanne Neschen, Gabi Kastenmüller, Christian Gieger, Michael Laxy, Freimut Schliess, Jerzy Adamski, Karsten Suhre, Martin Hrabě de Angelis, Annette Peters, Rui Wang‐Sattler	2021	12

About Markus F. Scheerer

Markus F. Scheerer is a scholar working on Endocrinology, Diabetes and Metabolism, Cardiology and Cardiovascular Medicine, Surgery, Complementary and alternative medicine and Molecular Biology, having authored 38 papers that have together received 753 indexed citations. Recurring topics across this work include Diabetes Treatment and Management (22 papers), Pancreatic function and diabetes (14 papers), Diabetes Management and Research (13 papers), Hormonal Regulation and Hypertension (11 papers), Metabolism, Diabetes, and Cancer (8 papers), Heart Failure Treatment and Management (7 papers), Cardiovascular Function and Risk Factors (4 papers) and Blood Pressure and Hypertension Studies (2 papers). The work is most often cited by research in Endocrinology, Diabetes and Metabolism (543 citations), Nephrology (66 citations), Surgery (290 citations), Cardiology and Cardiovascular Medicine (119 citations) and Pulmonary and Respiratory Medicine (110 citations). Markus F. Scheerer has collaborated with scholars based in Germany, United States and United Kingdom. Frequent co-authors include Moshe Phillip, Peter Rossing, Chantal Mathieu, Fredrik Thorén, Paresh Dandona, Nayyar Iqbal, Stefan D. Anker, John Xu, Luís M. Ruilope and Bertram Pitt. Their work appears in journals such as Diabetes, Diabetes Obesity and Metabolism, Journal of the American College of Cardiology, JACC Heart Failure and Journal of the American Society of Nephrology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact